• <a fr-original-style="" href="https://www.ft.com/content/9ee6ff98-81df-4c7e-a779-76de108fc6c2" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">AstraZeneca</a> agreed to buy US-based drug developer CinCor Pharma for up to $1.8 billion to expand its stock of heart and kidney drugs, said the Anglo-Swedish pharmaceutical company on Monday. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease.

CinCor Pharma ile ilgili hikayeler